Certolizumab pegol Completed Phase 2 Trials for Crohn's Disease (CD) Treatment

clinicaltrials.gov IdentifierTitleDrugs
NCT01190410Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
NCT00291668Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
NCT00329420Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
NCT00329550Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease